



Chandra Bhagat Pharma Limited

To,

Date: 14/11/2020

**The Manager,
Corporate Compliance Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai-400001.
Scrip Code: (BSE-542934)**

Sub:-Outcome of Board Meeting held on Saturday, 14th November, 2020 pursuant to the Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015(“Listing Regulation”).

Dear Sir/Madam,

The Board of Directors of the Company in their meeting held on 14th November, 2020 at Registered Office of Company viz. 323-F, Bhagat Bhuvan, Dr. Ambedkar Road, Matunga East, Mumbai-400019, which commenced at 05:00 pm and concluded at 06:00 pm inter alia, approved the Un-Audited Financial Result of the Company for the half year ended on 30th September, 2020 along with the Limited Review Report thereon furnished by the Statutory Auditor of the Company in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015.

In accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 and Company’s code of conduct for prohibition of Insider Trading, The “Trading Window” for trading in the shares of the Company will open after 48 hours from Announcement of Financial Statement for the Directors and Key Managerial Personnel/Designated Employees/ Connected person of the Company as defined in the code of conduct for prohibition of Insider Trading of the Company.



Chandra Bhagat Pharma Limited

Our company get listed on BSE SME plate form on 14/2/2020, hence Half Yearly Data of September, 2019 is not mentioned in our financial information.

Kindly take the above on record and inform all those concerned accordingly.

Yours Sincerely,

FOR CHANDRA BHAGAT PHARMA LIMITED

HEMANT C BHAGAT

Director

DIN: 00233530

**Limited Review Report on the half yearly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, As Amended****Review Report****To****The Board of Directors
Chandra Bhagat Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of **Chandra Bhagat Pharma Limited** (the 'Company') for the Half Year ended on September 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 and Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A Y & Company
Chartered Accountants
FRN: 020829C**
**Arpit Gupta
Partner****M. No. 421544****UDIN – 20421544AAAADG8344****Place: Mumbai****Date: 14.11.2020**

CHANDRA BHAGAT PHARMA LIMITED

CIN No: U24230MH2003PLC139534

323-F BHAGAT BHUVAN DR.AMBEDKAR ROAD MATUNGA (EAST) - MUMBAI MAHARASHTRA- 400019

Email : compliancecebe@gmail.com

Statement of Assets & Liabilities as at September 30, 2020

Particulars	As at September 30, 2020 (Amount in Rs.)	As at March 31, 2020 (Amount in Rs.)
	Unaudited	Audited
I. Equity and Liabilities		
Shareholders Fund		
Share Capital	75,450,560	75,450,560
Reserves & Surplus	181,783,730	181,438,714
	257,234,290	256,889,274
Non-current liabilities		
Long Term Borrowings	93,908,445	108,868,474
Deferred tax liabilities (Net)	-	2,121
Other Long Term Liabilities	40,913,040	40,919,440
	134,821,485	149,790,035
Current liabilities		
Short Term Borrowings	168,557,232	166,174,068
Trade payables		
(a) total outstanding dues of micro and small enterprises	-	-
(b) total outstanding dues other than micro and small enterprises	119,877,127	124,855,933
Other current liabilities	56,030,440	48,726,496
Short term Provisions	105,639	959,724
	344,570,438	340,716,221
Total	736,626,213	747,395,530
II. Assets		
Non-current assets		
Fixed assets		
Tangible Assets	4,394,129	4,358,285
Capital WIP	-	-
Intangible Assets	-	-
Other Non Current Assets	13,915,696	14,351,777
Deferred Tax Assets (Net)	34,638	-
	18,344,463	18,710,062
Current Assets		
Investments	7,571,759	7,456,644
Inventories	451,566,723	439,026,059
Trade Receivables	123,001,215	140,296,460
Cash & Bank Balances	15,396,684	524,376
Short Term loans & advances	120,222,788	136,984,323
Other current Assets	522,581	4,397,606
	718,281,750	728,685,468
Total	736,626,213	747,395,530

Notes:-

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 14, 2020
- The Statutory Auditors of the Company have carried out the Limited Review of these Results
- There are no investor complaints received/pending as on September 30, 2020
- Previous year/s/ period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.
- Since our company has been listed on SME Platform of BSE Limited on February 14, 2020 so that information related to Corresponding half year & Previous Half Year are not available with the company.

For Chandra Bhagat Pharma Limited

Hemant C Bhagat
Chairman Cum Managing Director
DIN : 00233530

Place : Mumbai
Date : November 14, 2020



CHANDRA BHAGAT PHARMA LIMITED

CIN No: U24230MH2003PLC139534

323-F BHAGAT BHUVAN DR.AMBEDKAR ROAD MATUNGA (EAST) - MUMBAI MAHARASHTRA- 400019

Email : compliancecbc@gmail.com

Statement of Unaudited Financial Results for the half year ended September 30, 2020 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

SR. NO.	Particulars	Six Months Ended on 30/09/2020 (Amount in Rs.)	Year to date figures for six months ended 30/09/2020 (Amount in Rs.)	Year to date figures for year ended 31/03/2020 (Amount in Rs.)
		Unaudited	Unaudited	Audited
	INCOME FROM OPERATIONS			
I	Revenue from Operations	223,644,110	223,644,110	939,809,030
II	Other Income	174,621	174,621	4,445,102
III	Total Income from Operations	223,818,731	223,818,731	944,254,132
IV	EXPENSES			
	Cost of Material Consumed	-	-	-
	Purchase of Stock in Trade	198,458,263	198,458,263	857,878,136
	Change in inventories of Finished Goods, WIP & Stock in Trade	(12,540,662)	(12,540,662)	110,006
	Employee benefit expenses	5,930,786	5,930,786	24,408,913
	Finance Cost	16,217,692	16,217,692	30,603,661
	Depreciation & Amortization Expense	104,126	104,126	319,170
	Other Expenses	15,234,630	15,234,630	26,710,208
	Total expenses (IV)	223,404,835	223,404,835	940,030,094
V	Profit/(loss) before Exceptional Items & Tax (III-IV)	413,896	413,896	4,224,038
VI	Exceptional Items	-	-	-
VII	Profit/(loss) before tax (VIII-IX)	413,896	413,896	4,224,038
X	Tax Expenses			
	1 Current Tax	105,639	105,639	959,724
	2 Deferred Tax	(36,759)	(36,759)	116,623
	Total Tax Expenses (XI)	68,880	68,880	1,076,347
XI	Profit/(Loss) after Tax (X-XI)	345,016	345,016	3,147,691
XII	Paid up Equity Share Capital	75,450,560	75,450,560	75,450,560
XIII	Reserves & Surplus	181,783,730	181,783,730	181,438,714
XIV	Earnings per equity share			
	(1) Basic	0.05	0.05	0.55
	(2) Diluted	0.05	0.05	0.55

For Chandra Bhagat Pharma Limited

Hemant C Bhagat
Chairman Cum Managing Director
DIN : 00233530

Place : Mumbai
Date : November 14, 2020



Chandra Bhagat Pharma Limited
(Formerly Known as Chandra Bhagat Pharma Private Limited)
CIN No: U24230MH2003PLC139534
Cash Flow Statement for the period ended September 30, 2020

Cash flow statement as at	30 September 2020 (Amount in Rs.)	31 March 2020 (Amount in Rs.)
Cash flow from operating activities		
Net Profit before tax and extraordinary items	413,896	4,224,038
Non-Cash adjustment to reconcile profit before tax to net cash flows		
Depreciation	104,126	319,170
Interest Received	(127,905)	(3,974,784)
Finance Cost	16,217,692	30,603,661
Operating profit before Working Capital changes	16,607,809	31,172,085
Change in Working Capital	26,641,439	(108,259,011)
Increase/(Decrease) in Trade Payables	(4,978,806)	(172,154,329)
Increase/(Decrease) in Other current Liabilities	6,344,219	(16,044,830)
Increase/(Decrease) in Short term Provision	-	-
Decrease/(Increase) in Inventories	(12,540,664)	110,006
Decrease/(Increase) in Trade receivables	17,295,245	122,681,980
Decrease/(Increase) in Short term Loans and advances	16,761,535	(79,775,001)
Decrease/(Increase) in Other Current Assets	3,875,025	4,041,789
Decrease/(Increase) in Investments	(115,115)	32,881,374
Cash generated from operations	43,249,248	(77,086,926)
Income Tax(Paid)/ Refund	-	-
Net Cash flow from / (used in) Operating activities (A)	43,249,248	(77,086,926)
Cash Flow from/(used in) Investing Activities		
Purchase of Fixed Assets	(139,969)	(38,078)
Interest received	127,905	3,974,784
(Increase)/Decrease in Other Non Current Assets	436,081	(3,434,777)
Net Cash (used in) investing activities (B)	424,017	501,929
Cash Flow from/ (used in) Financing Activities		
Finance Cost	(16,217,692)	(30,603,661)
Proceeds from issue of Share Capital	-	21,820,000
Proceeds from Security Premium	-	87,460,000
Proceeds/(Repayment) in Short term Borrowings	2,383,164	2,956,685
Proceeds/ (Repayment) of Long term Borrowings	(14,960,029)	(9,303,490)
Increase/(Decrease) in Long term Liabilities	(6,400)	-
Net Cash flow from / (used in) financing activities (C)	(28,800,957)	72,329,534
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	14,872,308	(4,255,463)
Cash and Cash Equivalents at the beginning of the year	524,376	4,779,839
Cash and Cash Equivalents at the end of the year	15,396,684	524,376

For Chandra Bhagat Pharma Limited

Mr. Hemant C. Bhagat
Chaiman cum Managing Director
DIN : 00233530



Place : Mumbai
Date : November 14, 2020